Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Incyte Corporation

Incyte Corporation (INCY) Stock Overview

Explore Incyte Corporation’s financial performance, market position, analyst ratings, and future outlook.

INCY●NASDAQ
HealthcareBiotechnology
$112.73
$1.40(1.23%)
U.S. Market opens in 11h 30m

Incyte Corporation (INCY)

Meyka AI Score

Z

Key Financials

Market Cap22.9B
P/E Ratio13.91
EPS (TTM)$7.44
ROE0.30%
Fundamental Analysis

AI Price Forecasts

1 Month$129.11
3 Months$141.43
1 Year Target$127.86

INCY Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Incyte Corporation (NASDAQ: INCY) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of A, Incyte Corporation's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of INCY on the NASDAQ shows an RSI of 29.38, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $127.86 for the NASDAQ listing.

Key metrics behind Incyte Corporation's NASDAQ-traded stock include a P/E ratio of 13.91 and a market capitalization of 22.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of INCY on the NASDAQ.

Price Performance (NASDAQ: INCY)

1-Day Change
-1.23%
5-Day Change
-6.42%
1-Month Change
-11.06%
3-Month Change
-2.50%
6-Month Change
18.84%
Year-to-Date (YTD) Change
14.13%
1-Year Change
29.23%
3-Year Change
96.63%
5-Year Change
71.27%
All-Time (Max) Change
5912.27%

Contact Information

https://www.incyte.com
302 498 6700
1801 Augustine Cut-Off, Wilmington, DE, 19803

Company Facts

28,440 Employees
IPO DateNov 4, 1993
CountryUS
Actively Trading

Frequently Asked Questions